Clomid Success Rate After 6 Consecutive Cycles
After six consecutive ovulatory cycles with clomiphene citrate, cumulative pregnancy rates reach approximately 67%, and continuing treatment for an additional six cycles (cycles 7-12) yields a cumulative ongoing pregnancy rate of 54% in women who ovulated but did not conceive in the first six cycles. 1
Success Rates by Treatment Duration
First Six Cycles
- Approximately 30% of patients achieve pregnancy during initial clomiphene citrate therapy 2
- In women with WHO Group II anovulation (normogonadotropic oligo/amenorrhea), cumulative conception rates reach 67% after six or more clomiphene-induced cycles 3
- The FDA label indicates that the majority of patients who will ovulate do so after the first course of therapy 2
Extended Treatment (Cycles 7-12)
- For women who ovulated in the first six cycles but did not conceive, continuing clomiphene citrate for cycles 7-12 results in a 54% cumulative ongoing pregnancy rate (95% CI 37-78%) 1
- 31% of women who failed to conceive in the first six ovulatory cycles achieved ongoing pregnancy when treatment was extended to 12 cycles 1
FDA-Approved Treatment Guidelines
The FDA recommends against treatment beyond six total cycles 2. Specific guidance includes:
- If three ovulatory responses occur without pregnancy, further treatment is not recommended 2
- If ovulation does not occur after three courses of therapy, further treatment with clomiphene citrate is not recommended and the patient should be reevaluated 2
- Long-term cyclic therapy is not recommended beyond a total of about six cycles 2
Clinical Considerations for Extended Treatment
When to Consider Continuation Beyond Six Cycles
Despite FDA labeling, recent evidence suggests that women with WHO type II anovulation who have ovulated for six cycles without conception may benefit from continuing clomiphene citrate rather than immediately switching to gonadotropins 1. This approach:
- Avoids the significantly higher multiple pregnancy rates associated with gonadotropins (14.8% vs 8.3%) 4
- Reduces treatment costs compared to gonadotropin therapy 5
- Maintains acceptable pregnancy rates while minimizing risks 1
Predictors of Success vs. Failure
Failure to ovulate after full-course clomiphene citrate is associated with:
Among women who ovulate, conception is associated with:
- Less frequent periods 3
- Higher basal LH levels 3
- Higher free testosterone and androstenedione levels 3
Multiple Pregnancy Risk
The overall incidence of multiple pregnancies with clomiphene citrate is approximately 8% 2:
This represents a substantially lower multiple pregnancy rate compared to gonadotropins (which range from 3.6% to 14.8%) 5, making clomiphene citrate a safer option from a morbidity standpoint when extended treatment is considered.
Practical Algorithm for Treatment Duration
Cycles 1-3: Continue if ovulation occurs; discontinue and reevaluate if no ovulation after three courses 2
Cycles 4-6: Continue if ovulation occurs without pregnancy; consider alternative therapy if three ovulatory cycles occur without conception per FDA guidance 2, though evidence supports continuation 1
Cycles 7-12: Consider continuation in women who have ovulated consistently, as this yields a 54% cumulative ongoing pregnancy rate 1, rather than immediately switching to more expensive and higher-risk gonadotropin therapy
After 12 ovulatory cycles: Switch to gonadotropin therapy if pregnancy has not occurred 1
Important Caveats
- Clomiphene citrate shows lower live birth rates compared to gonadotropins (OR = 1.8,95% CI 1.2-2.7 favoring gonadotropins) 5, but this must be balanced against the significantly lower multiple pregnancy risk
- Patients must be excluded from pregnancy between each treatment cycle 2
- Dosing should not exceed 100 mg/day for 5 days, as increasing dosage or duration beyond this does not improve outcomes 2